(Mayo Clinic) June 21, 2017 - A simple blood test could improve treatment for more than 1 in 6 stage 2 colon cancer patients, suggests new Mayo Clinic research. The researchers also discovered that many patients who could benefit from the test likely aren’t receiving it. The findings were published in the Journal of Gastrointestinal...
(eFFECTOR Therapeutics) June 20, 2017 – eFFECTOR Therapeutics announced today it has entered into a clinical collaboration and supply agreement with Pfizer and Merck KGaA, Darmstadt, Germany, to evaluate the combination of two immuno-oncology agents in patients with microsatellite stable colorectal cancer (CRC).
There are no Colorectal OBR Green articles.